Legend Biotech Corp 2023 SR
The report highlights Legend Biotech's inaugural ESG efforts for the 2023 fiscal year, focusing on its mission to develop transformative cell therapies like CARVYKTI. Key achievements include completing its first greenhouse gas inventory for Scope 1 and 2 emissions and formalizing its ESG strategy by aligning with SASB standards. The company emphasizes its commitment to patient access, employee engagement, and operational integrity, reporting a workforce of over 1,800 employees globally. Additionally, Legend Biotech established a Strategic Advisory Board and appointed an Executive Director of ESG to oversee its sustainability journey.
Company: Legend Biotech Corp
Sector: Health Care
Country: United States
Year: 2023
Type: SR
Pages: 41
Legend Biotech Corp
ESG Report
The report highlights Legend Biotech's inaugural ESG efforts for the 2023 fiscal year, focusing on its mission to develop transformative cell therapies like CARVYKTI. Key achievements include completing its first greenhouse gas inventory for Scope 1 and 2 emissions and formalizing its ESG strategy by aligning with SASB standards. The company emphasizes its commitment to patient access, employee engagement, and operational integrity, reporting a workforce of over 1,800 employees globally. Additionally, Legend Biotech established a Strategic Advisory Board and appointed an Executive Director of ESG to oversee its sustainability journey.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Published
Mar 19, 2024
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Women on Board
Employees